Pan-cancer characterization of ncRNA synergistic competition uncovers potential carcinogenic biomarkers
Fig 5
Drug resistance analysis of ncRNA synergistic competition networks and hub ncRNAs across malignant tumors.
(a) The number of significantly enriched drugs for each malignant tumor. (b) Relationships between ncRNA synergistic competition networks and enriched drugs. For example, the node “Network_ACC” denotes the ncRNA synergistic competition network in ACC. Larger drug nodes denote more links with ncRNA synergistic competition networks in malignant cancers. (c) Relationships between hub ncRNAs and enriched drugs. For example, the node “Hub_ACC” denotes the hub ncRNAs in ACC. Larger drug nodes denote more links with hub ncRNAs in malignant cancers.